Facebook
Twitter
Telegram
Report an ErrorAngion Biomedica Corp. Balance Sheet 2011-2024 | ANGN
Annual Balance Sheet Angion Biomedica Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-5.98 M | 1.32 M | -87.6 M | 17.5 M | - | - | - | - | - | - | - | - | - |
Long Term Debt |
6.01 M | 6.79 M | 235 K | 635 K | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
910 K | 692 K | 894 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 30.3 M | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
9.77 M | 6.87 M | 11.3 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
15.8 M | 13.7 M | 15 M | 138 M | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
694 K | 1.44 M | 2.3 M | 3.94 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-142 M | -107 M | -215 M | -161 M | - | - | - | - | - | - | - | - | - |
Total Assets |
27.1 M | 22.7 M | 96.5 M | 47.3 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
12.9 M | 6.16 M | 88.8 M | 34.6 M | - | - | - | - | - | - | - | - | - |
Book Value |
11.4 M | 8.92 M | 81.5 M | -90.4 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
11.4 M | -102 M | 81.5 M | -90.4 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Angion Biomedica Corp.
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
6.22 M | - | 6.79 M | 186 K | 202 K | 219 K | 235 K | - | - | - | 635 K | 635 K | 635 K | 635 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
17.7 M | 2.1 M | 13.7 M | 11.1 M | 11.1 M | 14.1 M | 15 M | 45.4 M | 48.2 M | 46.8 M | 138 M | 138 M | 138 M | 138 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.66 M | - | 1.44 M | - | - | 653 K | 2.3 M | 3.66 M | 5.18 M | 3.79 M | 3.94 M | 3.94 M | 3.94 M | 3.94 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-133 M | -258 M | -107 M | -248 M | -239 M | -229 M | -215 M | -230 M | -214 M | -197 M | -161 M | -161 M | -161 M | -161 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
31 M | 41.8 M | 22.7 M | 61.3 M | 70.8 M | 81.3 M | 96.5 M | 110 M | 125 M | 139 M | 47.3 M | 47.3 M | 47.3 M | 47.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
14.8 M | 29.2 M | 6.16 M | 1.84 M | 63.4 M | 73 M | 88.8 M | 103 M | 117 M | 130 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 5.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
13.3 M | 39.7 M | 8.92 M | 50.2 M | 59.8 M | 67.2 M | 81.5 M | 64.5 M | 77.2 M | 92.4 M | -90.4 M | -90.4 M | -90.4 M | -90.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
13.3 M | 39.7 M | -102 M | -95.7 M | 59.8 M | 67.2 M | 81.5 M | 64.5 M | 77.2 M | 92.4 M | -90.4 M | -90.4 M | -90.4 M | -90.4 M | -18.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency